Last reviewed · How we verify

Antipsychotic Maintenance — Competitive Intelligence Brief

Antipsychotic Maintenance (Antipsychotic Maintenance) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antipsychotic (typical or atypical). Area: Psychiatry / Mental Health.

marketed Antipsychotic (typical or atypical) Dopamine D2 receptor; serotonin 5-HT2A receptor (varies by specific agent) Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Antipsychotic Maintenance (Antipsychotic Maintenance) — University College, London. Antipsychotic maintenance therapy works by blocking dopamine and/or serotonin receptors in the brain to reduce psychotic symptoms and prevent relapse in patients with schizophrenia or bipolar disorder.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Antipsychotic Maintenance TARGET Antipsychotic Maintenance University College, London marketed Antipsychotic (typical or atypical) Dopamine D2 receptor; serotonin 5-HT2A receptor (varies by specific agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antipsychotic (typical or atypical) class)

  1. University College, London · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antipsychotic Maintenance — Competitive Intelligence Brief. https://druglandscape.com/ci/antipsychotic-maintenance. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: